GW Pharmaceuticals plc

GW Pharmaceuticals — Shareholder Meeting (March 2018)

33 slides from GW Pharmaceuticals's shareholder meeting presentation, Mar 14, 2018

  1. Slide 1: Annual General Meeting 14th March 2018

    ©2018 GW Pharmaceuticals plc | All Rights Reserved Annual General Meeting 14 th March 2018

  2. Slide 2: Forward-Looking Statements

    FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements that are based on our management’s beliefs and assumptions and on information currently available to management . Forward - looking statements include information about our current expectations for future events, in

  3. Slide 3: 2017-18 Highlights

    • Epidiolex Clinical / Medical Affairs - Dravet syndrome study published in New England Journal of Medicine - 1st LGS study published in The Lancet - Highly successful American Epilepsy Society meeting - Lifecyle management activity – new indications / formulations • Epidiolex Regulatory - NDA submi

  4. Slide 4: The Epidiolex Story: 3.5 Years from IND to NDA Submission

    The Epidiolex ® Story: 3.5 Years from IND to NDA Submission 3 Q4 ‘12 First child treated with Epidiolex Q1 ‘14 EAPs (Expanded Access Programs) initiated Q4 ‘14 Dravet 1 Part A started Q2 - 4 ‘15 3 Phase 3 studies in Dravet and LGS started and enrolled Q2 ‘14 FDA grants GW IND Formal GW CBD developme

  5. Slide 5: R&D Update

    R&D Update Dr. Volker Knappertz – Chief Medical Officer

  6. Slide 6: Epidiolex - FDA Review Timeline

    Epidiolex ® - FDA Review Timeline e Anticipate June 2017 July 2017 Aug 2017 Sept 2017 Oct 2017 Nov 2017 Dec 2017 Jan 2018 Feb 2018 Mar 2018 Apr 2018 May 2018 Jun 2018 Jul 2018 Aug 2018 Sep 2018 NDA Submission 27 Oct 2017 Day - 60 27 Dec PDUFA* Jun 27 2018 NDA Clock Starts 27 Oct AdComm 19 - Apr Epid

  7. Slide 7: FDA Advisory Committee Meeting April 19th

    FDA Advisory Committee Meeting April 19 th GW Pharmaceuticals • Peripheral and Central Nervous System Drug Advisory Committee » 8:00 am to 12:30 pm • Balanced presentation of product details and issues: » Sponsor presents data and position followed by Q&A » FDA presents data and position followed by

  8. Slide 8: Epidiolex - European Regulatory Process

    • Marketing Authorisation Application (MAA) submitted to the European Medicines Agency on December 29 th 2017 • Application validated in early February • Review conducted by rapporteur authorities, who submit their report to the Committee for Medicinal Products for Human Use (CHMP) • The review cloc

  9. Slide 9: CBDV Programme

    CBDV Programme 8 Autism Spectrum Disorders • CBDV chronically administered in two animal models has demonstrated it may be beneficial in treating some of the social and behavioral aspects of ASD (Rat Valproic Acid Model and BTBR Mouse model) • Orphan Drug Designation from FDA for CBDV for the treatm

  10. Slide 10: Sativex, Glioblastoma, NHIE and Discovery Pipeline

    • Sativex - Approved in > 25 countries for MS spasticity - New placebo - controlled trial data presented at ECTRIMS 2017 - Targeting FDA interaction in H 2 2018 , followed by a pivotal study in 2019 • CBD:THC for the treatment of Glioblastoma (GBM) - Phase II study completed - CBD:THC +TMZ showed a

  11. Slide 11: US Launch Preparation

    US Launch Preparation Julian Gangolli – President, North America

  12. Slide 12: US Commercialization through Greenwich Biosciences

    • In the U.S. we will use our subsidiary, Greenwich Biosciences Inc., to commercialize our products • Offices built - out in Carlsbad, CA to accommodate up to 120 - 130 Carlsbad based individuals - All Major US key commercial and organizational departments will be centered in Carlsbad • All Senior C

  13. Slide 13: US Market Overview

    • US is the World’s largest Pharmaceutical Market • Heavily regulated from a compliance perspective - Interactions with Health Care Professionals - Financial and Accounting reporting standards - Reporting to both individual State and Federal agencies • US Physicians have broad latitude to prescribe

  14. Slide 14: Epilepsy Prevalence and US Refractory Patient Population

    Epilepsy is the 4 th most common neurological disease, with 30% of patients being drug - resistant 13 50 Million People Suffered from Epilepsy The prevalence of Epilepsy in the US is 2.2 - 2.9 Million or 9.1/1000 The prevalence for children w/ Epilepsy in the us is 6.3/1000 or 466,000 30% of patient

  15. Slide 15: Majority of LGS and Dravet Patients Treated by 5,000 Prescribers

    Majority of LGS and Dravet patients are treated by 5,000 prescribers* 14 5000 Target Prescribers (12+ TRx* 12 months) 10,000 Pediatric / Adult Neurologists and Epileptologists 200 - 500 KOL’s National / Regional 16,000 Neurologists in the US Pediatric / Adult Neurologists and Epileptologists *Onfi,

  16. Slide 16: US Medical Affairs – Medical Science Liaison Professionals

    US Medical Affairs – 15 Medical Science Liaison Professionals 15 Cannabinoid, Disease State & Epidiolex Education Publications / Scientific Communications Key Congresses AES, AAN CNS Investigator Initiated Trials Educational Grants & Sponsorships Field - based Medical Science Liaisons Medical Inform

  17. Slide 17: American Epilepsy Society Meeting Dec 2017

    16 American Epilepsy Society Meeting Dec 2017 • Abstract / Poster Presentations - 16 GW and 13 Independent EAP posters presented • Innovation Pavilion - Nurses’ Hour (Demystifying Cannabis / Cannabinoids 101) - Across the Lifespan / Transition of Care - Demystifying Cannabis - Cannabinoids 101 • Inv

  18. Slide 18: Establishing the Highest Clinical Credentials for Cannabinoid Research

    17 Establishing the Highest Clinical Credentials for Cannabinoid Research Mar 2018 GW Pharmaceuticals plc AGM

  19. Slide 19: Prescriptions by Payer Type

    18 8 Out of 10 Prescriptions Are Estimated to Be Commercial or Medicaid Cash 2.9% Commercial 38.9% Managed Medicaid 28.4% FFS Medicaid 15.4% Medicare 12.3% Other 2.1% Payment Payer Type Mar 2018 GW Pharmaceuticals plc AGM

  20. Slide 20: Payer Advisors Expect Fair Formulary Review for Epidiolex

    19 Payer Advisors Believe Strong Data and Unmet Need Will Ensure a Fair Formulary Review for Epidiolex Unmet Treatment Needs: • Payers recognize the devastating burden to patients and care givers of Dravet Syndrome and LGS • Payers were intrigued by the HEOR cost offsets demonstrated by better seizu

  21. Slide 21: Distribution Plan Using Specialty Pharmacy and Distribution

    The Current Distribution Plan Will Use Specialty Pharmacy and Specialty Distribution to Put Epidiolex in the Patients’ Hands 20 Mar 2018 GW Pharmaceuticals plc AGM

  22. Slide 22: US Organization Structure

    USA ORGANIZATION Marketing Public Policy & Public Affairs Market Access & Payer Strategy Medical Affairs Sales Greenwich Biosciences Inc. US Structure Physician Programs Patient Advocacy Programs CRM Management 7 National Account Managers State Medicare Manager Government Reporting Health Economics

  23. Slide 23: Never losing focus of what matters most … the patients

    22 Never losing focus of what matters most … the patients Mar 2018 GW Pharmaceuticals plc AGM

  24. Slide 24: Manufacturing/Europe Update

    Manufacturing/Europe Update Chris Tovey – Chief Operating Officer

  25. Slide 25: A Year of Tremendous Progress in Capacity

    A Year Of Tremendous Progress In Capacity Manufacture Mar 2018 24 Growing Extraction Crystallisation/API Bulk & Filling/DP Labelling DP GW Pharmaceuticals plc AGM

  26. Slide 26: World Leading cGMP Extraction Expansion Project Underway

    World Leading cGMP Extraction Expansion Project Underway Mar 2018 25 October 2017 February 2018 March 2018 GW Pharmaceuticals plc AGM

  27. Slide 27: Successfully Launching Medicines in Europe

    Successfully Launching Medicines in Europe Mar 2018 26 Strong health economic argument over standard of care with real world evidence Strong negotiation of price by country Compound Education & Clinical differentiation to standard of care EMA approval Marketing and commercial readiness Key Commercia

  28. Slide 28: European Commercial Launch Organisation – Focus EU5

    European Commercial Launch Organisation – Focus EU5 Mar 2018 27 ~15 - 18 Sales Functional Support Country Leadership ~ 20 Medical Digital Model ~60 Staff in total ( GW:Syneos ) Senior Competency Specialists GW employees • Concentrated Customer Base • High Touch Model • US Synergy • Leverage Digital

  29. Slide 29: Finance Update

    Finance Update Scott Giacobello – Chief Financial Officer

  30. Slide 30: Foreign Private Issuer Status and Transition to Domestic Filer

    • GW is currently has Foreign Private Issuer (FPI) status - Report financials on Form 20 - F under International Financial Reporting Standards (IFRS) in Pounds Sterling - Benefit from exemption from proxy rules, more time to file periodic reports, etc. • Transition from FPI status to Domestic Filer

  31. Slide 31: Key Financial Data

    Key Financial Data Mar 2018 30 Clean up ICON Cash at 31 December 2017 $559.2m 2018 first half cash outflow guidance ($10m - $20m Capex, $100m - $110m Opex ) $100m - $120m Share Capital Current Options Fully Diluted ADS/m 28.2 1.0 29.2 GW Pharmaceuticals plc AGM

  32. Slide 32: Upcoming Milestones/Newsflow

    Upcoming Milestones/ Newsflow GW Pharmaceuticals plc AGM 31 Mar 2018 Expected Timing EPIDIOLEX REGULATORY NDA PDUFA June 27, 2018 EMA approval Q1 2019 DEA rescheduling Q3 2018 U.S. launch H2 2018 EPIDIOLEX DATA 2nd LGS Phase 3 publication H1 2018 Part A of two - part Phase 2/3 infantile spasms trial

  33. Slide 33: Thank You

    Thank You GW Pharmaceuticals plc NASDAQ: GWPH Stephen Schultz, VP Investor Relations sschultz@gwpharm.com + 1 401 - 500 - 6570

GW Pharmaceuticals — Shareholder Meeting (March 2018) on 6ix